UniQure files Huntington's gene therapy with FDA; Novo investor sentiment weak

UniQure has submitted its Huntington's disease gene therapy to the FDA for approval, a regulatory milestone for the first potential disease-modifying treatment. Investor enthusiasm for Novo Nordisk remains low amid pipeline and competitive concerns. The FDA filing is a key step but approval and commercial success are uncertain.